Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 5.

Grantham, Jared J; Chapman, Arlene B; Blais, Jaime; Czerwiec, Frank S; Devuyst, Olivier; Gansevoort, Ron T; Higashihara, Eiji; Krasa, Holly; Zhou, Wen; Ouyang, John; Perrone, Ronald D; Torres, Vicente E (2017). Tolvaptan suppresses monocyte chemotactic protein-1 excretion in autosomal-dominant polycystic kidney disease. Nephrology, Dialysis, Transplantation, 32(6):969-975.

Devuyst, Olivier; Chapman, Arlene B; Gansevoort, Ron T; Higashihara, Eiji; Perrone, Ronald D; Torres, Vicente E; Blais, Jaime D; Zhou, Wen; Ouyang, John; Czerwiec, Frank S (2017). Urine Osmolality, Response to Tolvaptan, and Outcome in Autosomal Dominant Polycystic Kidney Disease: Results from the TEMPO 3:4 Trial. Journal of the American Society of Nephrology (JASN), 28(5):1592-1602.

Casteleijn, Niek F; Blais, Jaime D; Chapman, Arlene B; Czerwiec, Frank S; Devuyst, Olivier; Higashihara, Eiji; Leliveld, Anna M; Ouyang, John; Perrone, Ronald D; Torres, Vicente E; Gansevoort, Ron T (2017). Tolvaptan and Kidney Pain in Patients With Autosomal Dominant Polycystic Kidney Disease: Secondary Analysis From a Randomized Controlled Trial. American Journal of Kidney Diseases, 69(2):210-219.

Gansevoort, Ron T; Meijer, Esther; Chapman, Arlene B; Czerwiec, Frank S; Devuyst, Olivier; Grantham, Jared J; Higashihara, Eiji; Krasa, Holly B; Ouyang, John; Perrone, Ronald D; Torres, Vicente E (2016). Albuminuria and tolvaptan in autosomal-dominant polycystic kidney disease: results of the TEMPO 3:4 Trial. Nephrology, Dialysis, Transplantation, 31(11):1887-1894.

Torres, Vicente E; Chapman, Arlene B; Devuyst, Olivier; Gansevoort, Ron T; Grantham, Jared J; Higashihara, Eiji; Perrone, Ronald D; Krasa, Holly B; Ouyang, John; Czerwiec, Frank S (2012). Tolvaptan in patients with autosomal dominant polycystic kidney disease. The New England Journal of Medicine, 367(25):2407-2418.

This list was generated on Sun Aug 19 11:44:12 2018 CEST.